Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies.

Ong, E; Viaccoz, A; Ducray, F; Pérol, M; Cavillon, G; Rogemond, V; Honnorat, J; Petiot, P

Ong, E; Viaccoz, A; Ducray, F; Pérol, M; Cavillon, G; Rogemond, V; Honnorat, J; Petiot, P.

Eur J Neurol ; 20(7): e96-7, 2013 Jul.

Article in En | MEDLINE | ID: mdl-23750840

Subject(s)

Antibodies, Monoclonal, Murine-Derived/therapeutic use; Autoantibodies/blood; Membrane Proteins/immunology; Nerve Tissue Proteins/immunology; Paraneoplastic Syndromes/drug therapy; Paraneoplastic Syndromes/immunology; Drug Resistance; Humans; Immunologic Factors/therapeutic use; Middle Aged; Paraneoplastic Syndromes/blood; Paraneoplastic Syndromes/diagnosis; Rituximab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Paraneoplastic Syndromes / Autoantibodies / Antibodies, Monoclonal, Murine-Derived / Membrane Proteins / Nerve Tissue Proteins Type of study: Diagnostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google